RBQM Updates for Clinical Experts

Jan 2025

Maximizing Site Readiness for ICH E6(R3)

By |2025-01-09T11:10:54+02:00January 9, 2025|Blog, News|Comments Off on Maximizing Site Readiness for ICH E6(R3)

The ICH E6(R3) guideline redefines expectations for clinical trial sites, emphasizing proactive planning, data accuracy, and risk monitoring to enhance participant safety and trial efficiency. Download our presentation for practical insights and strategies to ensure compliance and strengthen collaboration.

Dec 2024

Streamlining Clinical Trials: FDA Guidance Meets RBQM Strategy

By |2024-12-31T11:11:33+02:00December 31, 2024|News|Comments Off on Streamlining Clinical Trials: FDA Guidance Meets RBQM Strategy

The recently launched FDA’s draft guidance on protocol deviations highlights the importance of compliance and risk management. Combined with RBQM principles, sponsors can streamline trials, enhance safety, and align with regulations.

Dec 2024

ACDM Features RBQM Shift from ClinOps to Data Science

By |2024-12-31T10:31:39+02:00December 30, 2024|News|Comments Off on ACDM Features RBQM Shift from ClinOps to Data Science

Speaking at the 2nd Annual ACDM Symposium on RBQM, our CEO highlighted how RBQM has evolved from supporting Clinical Operations to becoming an integrated approach to data management.

Nov 2024

Empowering Trial Participants: The Right to Access Data and How Sponsors Can Deliver with Ease

By |2024-11-25T15:21:25+02:00November 25, 2024|Blog, Good Clinical Practice, News|Comments Off on Empowering Trial Participants: The Right to Access Data and How Sponsors Can Deliver with Ease

Clinical trial participants have the right to access their personal data, a principle emphasized in the ICH E6(R3) guidelines. Sponsors must ensure transparency and provide participants with their data in a clear and accessible format. Our Subject Profiles tool offers a streamlined solution, enabling sponsors to generate comprehensive reports efficiently, thereby meeting regulatory requirements and enhancing participant trust.

Nov 2024

Why Sponsors Should Embed RBQM Principles and Adaptive Monitoring Strategies in Protocol Design

By |2024-11-20T18:27:43+02:00November 19, 2024|Blog, News|Comments Off on Why Sponsors Should Embed RBQM Principles and Adaptive Monitoring Strategies in Protocol Design

This article explains why sponsors should adopt RBQM principles early in trial planning, supported by regulatory recommendations, and highlights the benefits of early implementation compared to addressing these elements later in the monitoring plan—or not at all.

Oct 2024

Navigating ICH E6(R3): New Standards for Medical Monitoring

By |2024-10-31T10:30:22+02:00October 30, 2024|AI in Clinical Trials, Blog, Good Clinical Practice, News|Comments Off on Navigating ICH E6(R3): New Standards for Medical Monitoring

Preparing for ICH E6(R3)? Discover how medical monitors can adapt to new safety, compliance, and data integrity standards with advanced monitoring tools.

Oct 2024

Cyntegrity Boosts Clinical Trial Efficiency with MongoDB Atlas

By |2024-10-23T13:33:07+02:00October 23, 2024|News|Comments Off on Cyntegrity Boosts Clinical Trial Efficiency with MongoDB Atlas

Cyntegrity leverages MongoDB Atlas to transform clinical trials, enhancing data integrity and accelerating drug development. Our AI-augmented MyRBQM® Portal empowers study teams to detect risks early, optimize costs, and ensure regulatory compliance, setting a new standard for safer, faster research. Discover how we’re driving the future of clinical trials.

Oct 2024

ISO 9001:2015 Renewal – Strengthening Quality in Clinical Research

By |2024-10-17T15:56:18+02:00October 17, 2024|Blog, News|Comments Off on ISO 9001:2015 Renewal – Strengthening Quality in Clinical Research

Cyntegrity is proud to announce the renewal of our ISO 9001:2015 certification. This renewal highlights our commitment to maintaining the highest standards of quality in clinical research, ensuring consistency, risk management, and regulatory compliance. Discover how this certification continues to drive our mission for excellence.

Sep 2024

EMA Releases New Guidelines for Safe Use of Large Language Models in Regulatory Science

By |2024-09-19T14:22:20+02:00September 19, 2024|AI in Clinical Trials, Good Clinical Practice, News|Comments Off on EMA Releases New Guidelines for Safe Use of Large Language Models in Regulatory Science

The EMA has released key guidelines on the responsible use of large language models (LLMs) in regulatory science. Discover how AI tools like GPT can streamline tasks while addressing privacy and accuracy challenges, and learn about the EMA’s approach to safe and ethical implementation.

Go to Top